Relation of Body Composition to Body Mass Index in HIV-infected Patients with Metabolic Abnormalities
Overview
Authors
Affiliations
Objective: To determine visceral adiposity (VAT), subcutaneous adiposity (SAT), and regional body adipose differences between HIV-infected and non-HIV-infected subjects in relation to body mass index (BMI) and World Health Organization BMI categories.
Design, Setting, And Participants: Analyses were conducted of 306 HIV-infected and 107 community-derived HIV-negative subjects evaluated for metabolic studies between 1999 and 2006. Analyses were stratified by gender. Additional analyses were performed stratifying subjects by metabolic syndrome status.
Results: HIV-infected men and women demonstrated decreased total extremity fat by 1.1 kg and 0.85 kg, respectively, relative to non-HIV-infected control subjects. VAT was increased among HIV-infected men and women in the normal (18.5 to 24.9 kg/m2) and overweight (25.0 to 29.9 kg/m2) categories relative to control subjects but not among those in the obese category (> or =30.0 kg/m2). In contrast, abdominal SAT was reduced among HIV-infected men in the normal and overweight categories but was similar among HIV-infected women and control subjects in these categories. Abdominal SAT was increased among HIV-infected women in the obese category relative to control subjects. Similar results were obtained limiting the analysis to HIV-infected (n = 204) and control subjects (n = 89) without the metabolic syndrome.
Conclusions: Peripheral lipoatrophy is a consistent finding among HIV-infected men and women with metabolic abnormalities. Relative increases in VAT are most pronounced among male and female HIV-infected subjects in the normal weight and overweight categories. Gender differences in abdominal SAT accumulation are observed, with preservation of SAT among HIV-infected women relative to control subjects.
Cardiometabolic Characteristics of Obesity Phenotypes in Persons With HIV.
Swartz A, Robles M, Park S, Esfandiari H, Bradshaw M, Koethe J Open Forum Infect Dis. 2024; 11(7):ofae376.
PMID: 39035569 PMC: 11259191. DOI: 10.1093/ofid/ofae376.
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Russo S, Ockene M, Arpante A, Johnson J, Lee H, Toribio M AIDS. 2024; 38(12):1758-1764.
PMID: 38905488 PMC: 11365754. DOI: 10.1097/QAD.0000000000003965.
Dirajlal-Fargo S, Jacobson D, Yu W, Mirza A, Geffner M, McComsey G HIV Med. 2023; 25(2):233-244.
PMID: 37845017 PMC: 10872855. DOI: 10.1111/hiv.13566.
Alonso-Pena M, Del Barrio M, Peleteiro-Vigil A, Jimenez-Gonzalez C, Santos-Laso A, Arias-Loste M Int J Mol Sci. 2023; 24(13).
PMID: 37445895 PMC: 10341551. DOI: 10.3390/ijms241310718.
Kure A, Abebe A, Baza D, Paulos W BMC Nutr. 2022; 8(1):62.
PMID: 35821078 PMC: 9275139. DOI: 10.1186/s40795-022-00556-1.